A New Match for Migraines
Aimovig (erenumab-aooe) approved to prevent migraines

The US Food and Drug Administration (FDA) has approved a new medication to prevent migraines.
It's called Aimovig (erenumab-aooe). The FDA approved this treatment, available as a monthly injection, to prevent migraines in adults. Aimovig is a new type of medication and the first of its kind.
This medication helps prevent migraines by blocking the calcitonin gene-related peptide, which is a molecule involved in migraine attacks.
Migraines affect about 10 percent of people across the globe, according to the FDA.
Those who have migraines tend to have recurring attacks, which are triggered by lack of food or sleep, stress, hormonal changes, bright or flashing lights and diet.
Common side effects of erenumab-aooe included injection-site reactions and constipation.
The FDA approved Aimovig for Amgen Inc.
Written By Anyssa Garza, PharmD, BCMAS
All information on this site is provided “as-is” for informational purposes only and is not a substitute for medical advice or treatment. You should consult with a medical professional if you have any questions about your health.
More health news
Health NewsNew Migraine Rx Approved
FDA approves Reyvow (lasmiditan) to treat migraines
Health NewsTwo New Ways to Prevent Migraines
FDA approves Ajovy and Emgality to prevent migraines
Health NewsNew Migraine Rx Gets Green Light
FDA approves Ubrelvy (ubrogepant) to treat migraines